Given Imaging and Micron Technology Announce Long-Term Exclusive Development and Supply Agreement

1/13/2003 - Yoqneam, Israel and Boise, Idaho -- Given Imaging, Ltd. (NASDAQ: GIVN) and Micron Technology, Inc. (NYSE: MU) today announced that they entered into an agreement whereby Micron will develop and supply current and next generation complementary metal-oxide semiconductor (CMOS) image sensors to Given Imaging. Micron’s CMOS image sensors are used in Given Imaging’s M2A capsule endoscope.

The five-year, mutually exclusive development and supply agreement includes the option of five one-year extensions, subject to approval by both parties. Given has been a valued customer of Micron since 2001.

"Micron’s leadership in process technology will enable us to incorporate next generation CMOS image sensors, promoting Given’s leadership in non-invasive gastrointestinal imaging technology," said Gavriel Meron, President and CEO of Given Imaging.

"The M2A capsule endoscope is a unique technology and a great example of the broad utility of our CMOS image sensor product line and our commitment to emerging markets. We are pleased to build on our relationship with Given Imaging and look forward to a long working relationship with them," said Steve Appleton, Chairman, CEO and President of Micron Technology.

About Micron Technology

Micron Technology, Inc., is one of the worlds leading providers of advanced semiconductor solutions used in todays leading-edge computing, consumer, networking, and communications products. Micron Technology, Inc., and its subsidiaries manufacture and market DRAMs, very fast SRAMs, Flash memory, TCAMs, CMOS image sensors, other semiconductor components and memory modules. Microns common stock is traded on the New York Stock Exchange (NYSE) under the MU symbol. To learn more about Micron Technology, Inc., visit its web site at www.micron.com.

This press release contains forward-looking statements about Given Imaging, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03